EUVIMEDEUVIMED entdecken
Multizentrische Studie

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223 Ra Therapy in Daily Practice

Joost H H M van Riel, Maarten L Donswijk, Christel Brouwer, Winald R Gerritsen, T T Ha Tan-Phan, Paul W L Thimister, Walter Noordzij, Erik T Te Beek, Laurence J C van Warmerdam, Andries M Bergman, Inge M van Oort, Dirk N J Wyndaele und 1 weitere

Journal of Nuclear Medicine · 2025

DOI: 10.2967/jnumed.125.269746 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Joost H H M van Riel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Radium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

223Ra-dichloride (223Ra) is an approved therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC) who have symptomatic bone metastases. After an initial course of 6 223Ra injections, treatment may be repeated. The purpose of this study was to evaluate the safety and efficacy of 223Ra retreatment of mCRPC in a real-world population.

Methods

This multicenter, retrospective cohort study included patients who had mCRPC and bone metastases who previously received 6 consecutive injections of 223Ra and received at least 1 223Ra retreatment injection between 2014 and 2024. The primary endpoint was safety, measured as hematologic and nonhematologic adverse events (AEs), including skeletal-related events. Secondary endpoints included the number of injections administered, overall survival, and biochemical response rates. Exploratory analyses intended to identify variables associated with alkaline phosphatase response during retreatment, completion of 223Ra retreatment, and overall survival.

Results

Sixty-one patients were evaluated. Median age was 75 y, 44% of patients received prior chemotherapy, and 87% of patients previously received at least 1 androgen receptor pathway inhibitor. The median number of prior systemic therapies was 3. In total, 56 patients (95%) experienced at least 1 hematologic AE, including 14% with grade 3 hematologic AEs. Forty-four patients (72%) experienced at least 1 nonhematologic AE during 223Ra retreatment. No grade 4 or 5 AEs occurred. Patients received a median of 6 223Ra retreatment injections. Overall survival was 16.9 mo (95% CI, 11.9-21.9 mo), and 56% of patients had an alkaline phosphatase response of at least 30%. High baseline hemoglobin levels, no prior chemotherapy, and a prostate-specific antigen response of at least 30% during the initial 223Ra course were predictors for completion of 6 223Ra retreatment injections. A prior skeletal-related event, baseline performance status, and baseline hemoglobin level were prognostic for survival in this population.

Conclusion

223Ra retreatment was well tolerated and is therefore deemed safe in selected patients with mCRPC. In addition, the high number of administered injections and the high alkaline phosphatase response rate suggest that retreatment is beneficial to patients with advanced mCRPC. Patients with high hemoglobin levels, good performance status, and prior prostate-specific antigen response to 223Ra therapy may be the best candidates for 223Ra retreatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantRadiumHumansMaleAgedRetrospective StudiesRetreatmentAged, 80 and overMiddle AgedNeoplasm MetastasisBone NeoplasmsTreatment OutcomeRadioisotopes

Stichwörter der Autor:innen

223Ra223Ra-dichloridemetastatic castration-resistant prostate cancerreal-world evidenceretreatment

Substanzen

Radiumradium Ra 223 dichlorideRadioisotopes

Autor:innen und Institutionen

  • Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Nuclear Medicine, Catharina Hospital, Eindhoven, The Netherlands.
  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Nuclear Medicine, Frisius Medical Center, Leeuwarden, The Netherlands.
  • Department of Nuclear Medicine, Admiraal de Ruyter Hospital, Goes, The Netherlands.

Zitieren

APA

van Riel, J. H. H. M., Donswijk, M. L., Brouwer, C., Gerritsen, W. R., Tan-Phan, T. T. H., Thimister, P. W. L., Noordzij, W., Te Beek, E. T., van Warmerdam, L. J. C., Bergman, A. M., van Oort, I. M., Wyndaele, D. N. J., & van der Doelen, M. J. (2025). Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223 Ra Therapy in Daily Practice. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269746

Vancouver

van Riel JHHM, Donswijk ML, Brouwer C, Gerritsen WR, Tan-Phan TTH, Thimister PWL, et al. Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223 Ra Therapy in Daily Practice. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.269746

BibTeX
@article{vanRiel2025,
  author = {van Riel, Joost H H M and Donswijk, Maarten L and Brouwer, Christel and Gerritsen, Winald R and Tan-Phan, T T Ha and Thimister, Paul W L and Noordzij, Walter and Te Beek, Erik T and van Warmerdam, Laurence J C and Bergman, Andries M and van Oort, Inge M and Wyndaele, Dirk N J and van der Doelen, Maarten J},
  title = {Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223 Ra Therapy in Daily Practice},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  doi = {10.2967/jnumed.125.269746}
}
Kostenlos starten →